MedTrace Logo

Treatment of Moderate to Severe Glabellar Lines (BMI2006)

NCT05531968 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 278

Last updated 2022-09-08

No results posted yet for this study

Summary

A multicenter, double-blind, randomized, parallel design, active control, phase 3 clinical trial to evaluate the efficacy and safety of 100 units of BMI 2006 and Botox® in adult patients in need of moderate or severe glabellar lines

Conditions

  • Glabellar Lines

Interventions

BIOLOGICAL

BMI2006

IM

BIOLOGICAL

BOTOX®

IM

Sponsors & Collaborators

  • BMI Korea

    lead INDUSTRY

Principal Investigators

  • Beom Joon Kim, MD, Ph.D. · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-09
Primary Completion
2021-08-10
Completion
2021-09-17

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05531968 on ClinicalTrials.gov